Your browser doesn't support javascript.
loading
Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study.
Doi, Toshihiko; Shitara, Kohei; Naito, Yoichi; Shimomura, Akihiko; Fujiwara, Yasuhiro; Yonemori, Kan; Shimizu, Chikako; Shimoi, Tatsunori; Kuboki, Yasutoshi; Matsubara, Nobuaki; Kitano, Atsuko; Jikoh, Takahiro; Lee, Caleb; Fujisaki, Yoshihiko; Ogitani, Yusuke; Yver, Antoine; Tamura, Kenji.
Afiliação
  • Doi T; Department of Experimental Therapeutics, National Cancer Center Hospital East, Chiba, Japan. Electronic address: tdoi@east.ncc.go.jp.
  • Shitara K; Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan.
  • Naito Y; Department of Experimental Therapeutics, National Cancer Center Hospital East, Chiba, Japan; Department of Breast and Medical Oncology, National Cancer Center Hospital East, Chiba, Japan.
  • Shimomura A; Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
  • Fujiwara Y; Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
  • Yonemori K; Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
  • Shimizu C; Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
  • Shimoi T; Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
  • Kuboki Y; Department of Experimental Therapeutics, National Cancer Center Hospital East, Chiba, Japan.
  • Matsubara N; Department of Breast and Medical Oncology, National Cancer Center Hospital East, Chiba, Japan.
  • Kitano A; Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
  • Jikoh T; Research & Development, Daiichi Sankyo Inc, Basking Ridge, NJ, USA.
  • Lee C; Research & Development, Daiichi Sankyo Inc, Basking Ridge, NJ, USA.
  • Fujisaki Y; Oncology Clinical Development Department, Daiichi Sankyo Co, Ltd, Tokyo, Japan.
  • Ogitani Y; Biologics & Immuno-Oncology Laboratories, Daiichi Sankyo Co, Ltd, Tokyo, Japan.
  • Yver A; Research & Development, Daiichi Sankyo Inc, Basking Ridge, NJ, USA.
  • Tamura K; Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
Lancet Oncol ; 18(11): 1512-1522, 2017 11.
Article em En | MEDLINE | ID: mdl-29037983
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Gástricas / Neoplasias da Mama / Neoplasias Esofágicas / Receptor ErbB-2 / Anticorpos Monoclonais Humanizados / Trastuzumab Tipo de estudo: Clinical_trials / Prognostic_studies País/Região como assunto: Asia Idioma: En Ano de publicação: 2017 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Gástricas / Neoplasias da Mama / Neoplasias Esofágicas / Receptor ErbB-2 / Anticorpos Monoclonais Humanizados / Trastuzumab Tipo de estudo: Clinical_trials / Prognostic_studies País/Região como assunto: Asia Idioma: En Ano de publicação: 2017 Tipo de documento: Article